

FILE 'MEDLINE' ENTERED AT 12:41:37 ON 14 APR 1997
 'BIOSIS' ENTERED AT 12:41:37 ON 14 APR 1997
 COPYRIGHT (C) 1997 BIOSIS(R) FILE 'CA' ENTERED AT 12:41:37
 ON 14 APR 1997
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)
 FILE 'INPADOC' ENTERED AT 12:41:37 ON 14 APR 1997
 COPYRIGHT 1997 (C) European Patent Office, Vienna (EPO) FILE
 'WPIDS' ENTERED AT 12:41:37 ON 14 APR 1997
 COPYRIGHT (C) 1997 DERWENT INFORMATION LTD FILE 'JICST-
 EPLUS' ENTERED AT 12:41:37 ON 14 APR 1997
 COPYRIGHT (C) 1997 Japan Science and Technology Corporation (JST)
 => s interferon? and (composition and (mannitol and albumin and acetate))
 L2 0 FILE MEDLINE
 L3 0 FILE BIOSIS
 L4 0 FILE CA
 L5 0 FILE INPADOC
 L6 2 FILE WPIDS
 L7 0 FILE JICST-EPLUS TOTAL FOR ALL FILES
 L8 2 INTERFERON? AND ((COMPOSITION AND (MANNITOL AND
 ALBUMIN AND
 ACETATE))
 => d 1-2 bib ab
 L8 ANSWER 1 OF 2 WPIDS COPYRIGHT 1997 DERWENT INFORMATION
 LTD
 AN 89-165513 [22] WPIDS
 DNC C89-073478
 TI Stable liq. compsn. contg. non-lyophilised gamma *interferon*
 - and pref. buffer, sugar alcohol stabiliser and nonionic detergent.
 DC B04
 IN HWANG-FELGNER, J; JONES, R E; MAHER, J F; HWANGFELGN, J Y
 PA (GETH) GENENTECH INC
 CYC 24
 PI WO 8904177 A 890518 (8922)* EN 14 pp
 RW: AT BE CH DE FR GB IT LI LU NL SE
 W: AU DK FI HU JP KR NO
 AU 8827245 A 890601 (8934)
 PT 88918 A 890914 (8941)
 ZA 8808249 A 900725 (9034)
 EP 386106 A 900912 (9037)
 R: AT BE CH DE FR GB IT LI LU NL SE
 JP 03500882 W 910228 (9115)
 DD 289470 A 910502 (9139)
 US 5151265 A 920929 (9242) 4 pp
 IL 88233 A 930818 (9340)
 EP 386106 B1 940302 (9409) EN 7 pp
 R: AT BE CH DE FR GB IT LI LU NL SE
 DE 3888197 G 940407 (9415)
 CA 1335176 C 950411 (9522)
 ADT WO 8904177 A WO 88-US3883 881101; ZA 8808249 A ZA 88-8249
 881103; EP 386106 A EP 88-910211 881101; JP 03500882 W JP 88-509401 881101; US
 5151265 A Cont of US 87-116434 871103, US 90-514392 900425; IL 88233
 A IL 88-88233 881030; EP 386106 B1 EP 88-910211 881101, WO 88-US3883
 881101; DE 3888197 G DE 88-3888197 881101, EP 88-910211 881101, WO
 88-US3883 881101; CA 1335176 C CA 88-582102 881103
 FDT EP 386106 B1 Based on WO 8904177; DE 3888197 G Based on EP
 386106,
 Based on WO 8904177
 PRAI US 87-116434 871103
 AB WO 8904177 A UPAB: 930923
 Liq. pharmaceutical compsns. contg. non-lyophilised gamma-
 interferon (I) are new. The compsn. includes an organic
 acid buffer to pH 4-6 (e.g. citrate, succinate, tartrate, fumarate,
 gluconate, oxalate, lactate or *acetate*); a stabiliser
 (esp. a polyhydric alcohol such as glycerol, erythritol, arabitol,
 xylitol, sorbitol or *mannitol*) and a nonionic detergent.
 ADVANTAGE - The compsn. is stable to fluctuations in temp. and
 can be stored for a long time (over 2 weeks) before administration.
 By eliminating the lyophilisation step, formation of dimers and
 oligomers is avoided; no bulking or stabilising agent (such as
 possibly contaminated human serum *albumin*) is needed and
 compsns. can be prepd. more cheaply.
 0/0

L8 ANSWER 2 OF 2 WPIDS COPYRIGHT 1997 DERWENT INFORMATION
 LTD
 AN 83-772523 [39] WPIDS
 DNC C83-092497
 TI Stable *interferon* beta compsn. - with highly purified
 interferon beta in buffer contg. polyvinyl-pyrrolidone.
 DC A96 B04 D16
 IN SYMBALLIST, S
 PA (INT-N) INTER-YEDA LTD
 CYC 16
 PI EP 89245 A 830921 (8339)* EN 13 pp
 R: AT BE CH DE FR GB IT LI NL SE
 AU 8312343 A 830922 (8345)
 BE 897276 A 831103 (8348)
 JP 59010598 A 840120 (8409)
 ES 8500062 A 850101 (8510)
 IL 65277 A 850331 (8517)
 CA 1209473 A 860812 (8637)
 US 4647454 A 870303 (8711)
 ADT JP 59010598 A JP 83-41624 830315; US 4647454 A US 83-475177
 830314
 PRAI IL 82-65277 820317
 AB EP 89245 A UPAB: 930925
 Stable *interferon* beta (I) compsn. comprises a buffered
 soln. of highly purified (I) with excipients and 0.5-10 wt./vol.% of
 polyvinylpyrrolidone (PVP). The compsns. are storage stable in
 contrast to the lyophilised highly purified (I) alone. (I) is a
 highly active antiviral protein.
 The excipients include *mannitol* and human serum
 albumin. The buffer is suitable *acetate* buffer at
 pH 3.5. The compsn. may be lyophilised and sealed in a container in
 vacuo.
 0/0
 => s interferon? and ((mannitol or albumin or acetate))
 L9 1493 FILE MEDLINE
 L10 1299 FILE BIOSIS
 L11 1408 FILE CA
 L12 4 FILE INPADOC
 L13 210 FILE WPIDS
 L14 388 FILE JICST-EPLUS TOTAL FOR ALL FILES
 L15 4802 INTERFERON? AND ((MANNITOL OR ALBUMIN OR
 ACETATE))
 => s l15 and interferon beta
 L16 48 FILE MEDLINE
 L17 45 FILE BIOSIS
 L18 71 FILE CA
 L19 0 FILE INPADOC
 L20 12 FILE WPIDS
 L21 15 FILE JICST-EPLUS TOTAL FOR ALL FILES
 L22 191 L15 AND INTERFERON BETA
 => s l22 an pharmaceut?
 MISSING OPERATOR 'L22 AN'
 The search profile that was entered contains terms or
 nested terms that are not separated by a logical operator.
 => s l22 and pharmaceut?
 L23 0 FILE MEDLINE
 L24 0 FILE BIOSIS
 L25 12 FILE CA
 L26 0 FILE INPADOC
 L27 2 FILE WPIDS
 L28 2 FILE JICST-EPLUS TOTAL FOR ALL FILES
 L29 16 L22 AND PHARMACEUT?
 => dup rem l29
 PROCESSING COMPLETED FOR L29
 L30 13 DUP REM L29 (3 DUPLICATES REMOVED)
 => d 1-13 ti
 L30 ANSWER 1 OF 13 CA COPYRIGHT 1997 ACS
 TI Dry powder formulation of *interferons*
 L30 ANSWER 2 OF 13 CA COPYRIGHT 1997 ACS
 TI Process for preparing micronized polypeptide drugs
 L30 ANSWER 3 OF 13 JICST-EPlus COPYRIGHT 1997 JST
 TI Design of database for dermatologic inpatients in Yokohama City
 University Hospital and statistical analysis.
 L30 ANSWER 4 OF 13 CA COPYRIGHT 1997 ACS

TI Improved process for preparing micronized polypeptide drugs
 L30 ANSWER 5 OF 13 CA COPYRIGHT 1997 ACS
 TI Preparation of *pharmaceutical* compositions containing human B cell differentiation factor
 L30 ANSWER 6 OF 13 CA COPYRIGHT 1997 ACS
 TI Stable *interferon* - . *beta* . preparations containing metal salts and albumins
 L30 ANSWER 7 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 1
 TI *Pharmaceutical* compositions containing recombinant *interferon* - . *beta* .
 L30 ANSWER 8 OF 13 CA COPYRIGHT 1997 ACS
 TI Stabilization of *interferon* - . *beta* . in *pharmaceuticals*
 L30 ANSWER 9 OF 13 CA COPYRIGHT 1997 ACS
 TI Antitumor *pharmaceuticals* containing *interferons* and dipyridamole
 L30 ANSWER 10 OF 13 CA COPYRIGHT 1997 ACS
 TI *Pharmaceutical* injections containing recombinant beta-*interferons* and nonionic surfactants and sugars as stabilizers
 L30 ANSWER 11 OF 13 CA COPYRIGHT 1997 ACS
 TI Controlled-release of macromolecular polypeptides
 L30 ANSWER 12 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 2
 TI Enzyme immunoassay of human fibroblast *interferon* after intranasal administration with several excipients in rabbits
 L30 ANSWER 13 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 3
 TI Improved formulation for recombinant .beta.- *interferon* with protein or sugar stabilizer
 => d 1-13 bib
 L30 ANSWER 1 OF 13 CA COPYRIGHT 1997 ACS
 AN 124:97762 CA
 TI Dry powder formulation of *interferons*
 IN Platz, Robert M.; Kimura, Narinobu; Satoh, Oichiro; Foster, Linda C.
 PA Inhale Therapeutic Systems, Inc., USA
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 PI WO 9531479 A1 951123
 DS W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 95-US6008 950515
 PRAI US 94-246034 940518
 DT Patent
 LA English
 L30 ANSWER 2 OF 13 CA COPYRIGHT 1997 ACS
 AN 121:308338 CA
 TI Process for preparing micronized polypeptide drugs
 IN Platz, Robert M.; Ip, Anna; Whitham, Clyde L.
 PA SRI International, USA
 SO U.S., 5 pp. Cont.-in-part of U.S. Ser. No. 823,218, abandoned.
 CODEN: USXXAM
 PI US 5354562 A 941011
 AI US 93-17540 930216
 PRAI US 92-823218 920121
 DT Patent
 LA English
 L30 ANSWER 3 OF 13 JICST-EPlus COPYRIGHT 1997 JST
 AN 950277710 JICST-EPlus
 TI Design of database for dermatologic inpatients in Yokohama City University Hospital and statistical analysis.
 AU IWATA MASANORI; NAKAMURA YASUKO; SHIROTAKE SHOICHI NISHIYAMA TAKAFUMI; ISHII NORIHISA; NAKAJIMA HIROSHI CS Yokohama City Univ., Sch. of Med., Hosp.
 Yokohama City Univ., Sch. of Med.
 SO Yokohama Igaku (Yokohama Medical Journal), (1994) vol. 45, no. 6, pp. 687-691. Journal Code: G0703A (Fig. 5, Tbl. 2, Ref. 10)
 CODEN: YKIGAK; ISSN: 0372-7726
 CY Japan
 DT Journal; Short Communication
 LA Japanese
 STA New

L30 ANSWER 4 OF 13 CA COPYRIGHT 1997 ACS
 AN 119:125242 CA
 TI Improved process for preparing micronized polypeptide drugs
 IN Platz, Robert M.; Ip, Anna; Witham, Clyde L.
 PA SRI International, USA
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 PI WO 9313752 A1 930722
 DS W: CA, JP
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AI WO 93-US373 930120
 PRAI US 92-823218 920121
 DT Patent
 LA English
 L30 ANSWER 5 OF 13 CA COPYRIGHT 1997 ACS
 AN 115:120026 CA
 TI Preparation of *pharmaceutical* compositions containing human B cell differentiation factor
 IN Kishimoto, Chiyuzo; Hirano, Chiyuzo; Akiyama, Yukio; Okano, Akira
 PA Ajinomoto Co., Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 PI JP 03027320 A2 910205 Heisei
 AI JP 89-163088 890626
 DT Patent
 LA Japanese
 L30 ANSWER 6 OF 13 CA COPYRIGHT 1997 ACS
 AN 113:103445 CA
 TI Stable *interferon* - . *beta* . preparations containing metal salts and albumins
 IN Yamazaki, Shojiro; Taniguchi, Makoto; Hara, Michio
 PA Toray Industries, Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 PI JP 02124832 A2 900514 Heisei
 AI JP 89-174811 890705
 PRAI JP 88-171491 880708
 DT Patent
 LA Japanese
 L30 ANSWER 7 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 1
 AN 111:239534 CA
 TI *Pharmaceutical* compositions containing recombinant *interferon* - . *beta* .
 IN Taforo, Terrance; Thomson, Jody; Shaked, Ze'ev; Hershenson, Susan; Thomson, James W.; Stewart, Tracy
 PA Cetus Corp., USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 PI WO 8902750 A1 890406
 DS W: AU, DK, JP, NO
 RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
 AI WO 88-US3313 880926
 PRAI US 87-100679 870929
 DT Patent
 LA English
 L30 ANSWER 8 OF 13 CA COPYRIGHT 1997 ACS
 AN 113:65247 CA
 TI Stabilization of *interferon* - . *beta* . in *pharmaceuticals*
 IN Hara, Michio; Taniguchi, Makoto
 PA Toray Industries, Inc., Japan
 SO PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 PI WO 8910756 A1 891116
 DS W: JP
 RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
 AI WO 89-JP466 890502
 PRAI JP 88-110921 880506
 DT Patent
 LA Japanese
 L30 ANSWER 9 OF 13 CA COPYRIGHT 1997 ACS
 AN 110:237165 CA
 TI Antitumor *pharmaceuticals* containing *interferons* and dipyridamole

IN Suzuki, Nobuo; Takakubo, Yoshiaki
 PA Boehringer Ingelheim International G.m.b.H., Fed. Rep. Ger.
 SO Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 PI EP 295317 A1 881221
 DS R: GB
 AI EP 87-108708 870616
 DT Patent
 LA English
 L30 ANSWER 10 OF 13 CA COPYRIGHT 1997 ACS
 AN 110:179532 CA
 TI *Pharmaceutical* injections containing recombinant beta-*interferons* and nonionic surfactants and sugars as stabilizers
 IN Shaked, Zeev; Stewart, Tracy; Thomson, Jody; Thomson, James William; Taforo, Terrance; Hershenson, Susan
 PA Cetus Corp., USA
 SO Eur. Pat. Appl., 83 pp.
 CODEN: EPXXDW
 PI EP 270799 A1 880615
 DS R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
 AI EP 87-115693 871026
 PRAI US 86-923423 861027
 DT Patent
 LA English
 L30 ANSWER 11 OF 13 CA COPYRIGHT 1997 ACS
 AN 109:216010 CA
 TI Controlled-release of macromolecular polypeptides
 IN Eppstein, Deborah Ann; Schryver, Brian Bloor
 PA Syntex (U.S.A.), Inc., USA
 SO Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 PI EP 251476 A1 880107
 DS R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
 AI EP 87-304570 870522
 PRAI US 86-866625 860523
 DT Patent
 LA English
 L30 ANSWER 12 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 2
 AN 109:215865 CA
 TI Enzyme immunoassay of human fibroblast *interferon* after intranasal administration with several excipients in rabbits
 AU Igawa, Takeshi; Maitani, Yoshie; Machida, Yoshiharu; Nagai, Tsuneji
 CS Fac. Pharm. Sci., Hoshi Univ., Tokyo, 142, Japan
 SO Chem. Pharm. Bull. (1988), 36(8), 3055-9
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 L30 ANSWER 13 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 3
 AN 107:183557 CA
 TI Improved formulation for recombinant .beta.- *interferon* with protein or sugar stabilizer
 IN Hanisch, Wolfgang Helmut; Taforo, Terrance; Fernandes, Peter Michael
 PA Cetus Corp., USA
 SO Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 PI EP 215658 A2 870325
 DS R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE
 AI EP 86-307070 860912
 PRAI US 85-775751 850913
 DT Patent
 LA English
 => d 1-13 bib ab
 L30 ANSWER 1 OF 13 CA COPYRIGHT 1997 ACS
 AN 124:97762 CA
 TI Dry powder formulation of *interferons*
 IN Platz, Robert M.; Kimura, Narinobu; Satoh, Oichiro; Foster, Linda C.
 PA Inhale Therapeutic Systems, Inc., USA
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 PI WO 9531479 A1 951123
 DS W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 95-US6008 950515
 PRAI US 94-246034 940518
 DT Patent
 LA English
 AB Spray-dried, *interferon* -based dry powder formulations, particularly of *interferon* -. *beta* ., are provided for treating conditions in humans that are responsive to treatment with *interferons* by pulmonary delivery. Spray drying produces stable, high-potency dry powder formulations of *interferons*. Thus, 100 mL 10 mM NaCl soln. contg. 7 .times. 104 IU *interferon* /mL, 150 mg *mannitol* /mL, and 2 mg human serum *albumin* /mL was spray dried (inlet temp. 100.degree., outlet temp. 60.degree., feed rate of soln. 4.3 mL/min) with 81% retention of *interferon* activity.
 L30 ANSWER 2 OF 13 CA COPYRIGHT 1997 ACS
 AN 121:308338 CA
 TI Process for preparing micronized polypeptide drugs
 IN Platz, Robert M.; Ip, Anna; Whitham, Clyde L.
 PA SRI International, USA
 SO U.S., 5 pp. Cont.-in-part of U.S. Ser. No. 823,218, abandoned.
 CODEN: USXXAM
 PI US 5354562 A 941011
 AI US 93-17540 930216
 PRAI US 92-823218 920121
 DT Patent
 LA English
 AB Solid particle aerosol formulations of polypeptide drugs are made by lyophilizing solns. of the drugs which contain milling stabilizers that inhibit degrdn. of the drug during subsequent milling. The lyophilized drug is milled in fluid energy mills that have been fitted with abrasion-resistant materials and which use pure nitrogen that has been filtered to eliminate particles of greater than 0.1 .nu.m to transport the drug. The use of (a) milling stabilizers in the soln. and (b) abrasion-resistant fluid energy mills that use pure filtered nitrogen in the milling step reduce insol. contaminants and inactive fractions in the milled product. Micronization of human growth hormone, *interferon* -. *beta* ., and granulocyte colony-stimulating factor are described.
 L30 ANSWER 3 OF 13 JICST-EPlus COPYRIGHT 1997 JST
 AN 950277710 JICST-EPlus
 TI Design of database for dermatologic inpatients in Yokohama City University Hospital and statistical analysis.
 AU IWATA MASANORI; NAKAMURA YASUKO; SHIROTAKE SHOICHI NISHIYAMA TAKAFUMI; ISHII NORIHISA; NAKAJIMA HIROSHI
 CS Yokohama City Univ., Sch. of Med., Hosp.
 Yokohama City Univ., Sch. of Med.
 SO Yokohama Igaku (Yokohama Medical Journal), (1994) vol. 45, no. 6, pp. 687-691. Journal Code: G0703A (Fig. 5, Tbl. 2, Ref. 10)
 CODEN: YKIGAK; ISSN: 0372-7726
 CY Japan
 DT Journal; Short Communication
 LA Japanese
 STA New
 AB *Pharmaceutical* services of a Dermatology Ward were investigated. Since Yokohama City University Hospital opened in 1991, pharmacists have joined a medical team of the Dermatology Ward. The data base of the inpatients was designed using a personal computer and the data were processed statistically. Five hundred cases(342 patients) were treated over 3 years at the Dermatology Ward of the hospital. The total number of inpatients of malignant melanoma was 84, and that of atopic dermatitis was 48. The patients of malignant melanoma increased among the aged. On the other hand, the patients of atopic dermatitis were concentrated among the youngers. Chemotherapy using dacarbazine, nimustin HCl, vincristine sulfate and *interferon* -. *BETA* .(DAV-INF) were taken in 43 cases of malignant melanoma. Ketotifen fumarate(anti allergic agent, 22 cases), hydroxyzine(antihistamine, 21 cases) were taken for atopic dermatitis. As local therapy, many kinds of steroid ointments were applied to the inpatients of atopic dermatitis. The files prepared by pharmacists are supplying clear data on inpatients

to dermatologists. In the future, the role of pharmacist in the medical team will become more important along with the improvement of the *pharmaceutical* circumstances of the hospital.
(author abst.)

L30 ANSWER 4 OF 13 CA COPYRIGHT 1997 ACS
AN 119:125242 CA

TI Improved process for preparing micronized polypeptide drugs
IN Platz, Robert M.; Ip, Anna; Witham, Clyde L.

PA SRI International, USA
SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2
PI WO 9313752 A1 930722

DS W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AI WO 93-US373 930120

PRAI US 92-823218 920121
DT Patent
LA English

AB Solid particle aerosol formulations of polypeptide drugs are prep'd. by (1) lyophilizing drug solns. which contain milling stabilizers and (2) milling the lyophilized drug in a fluid energy mill using a pure inert gas, preferably N₂. Use of milling stabilizers in the soln. and the pure filtered gas in the milling step reduces insol. contaminants and inactive fractions in the milled product.
Micronization of *interferon* - . *beta* . with human serum *albumin* as a milling stabilizer is demonstrated.

L30 ANSWER 5 OF 13 CA COPYRIGHT 1997 ACS
AN 115:120026 CA
TI Preparation of *pharmaceutical* compositions containing human B cell differentiation factor
IN Kishimoto, Chiyuzo; Hirano, Chiyuzo; Akiyama, Yukio; Okano, Akira
PA Ajinomoto Co., Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

PI JP 03027320 A2 910205 Heisei
AI JP 89-163088 890626
DT Patent

LA Japanese

AB Human B cell differentiation factor (BCDF) is stabilized and incorporated into *pharmaceutical* compns., and 2 amino acid sequences of the BCDF are given. Blood serum proteins (albumins, or .alpha.2-macroglobulins) are used as solubilizers or stabilizers. Human BCDF was produced in culture medium of Escherichia coli by recombinant DNA method. Then, 50 .mu.L 20% human serum *albumin* soln. (Na 3.3, Cl 3.1, Na caprylate 2.659, acetyltryptophan Na 4.2925 mg/mL) was added to 200 .mu.L human BCDF (20 .mu.g/mL, phosphate buffer soln.), and dild. to 4 mL with saline. This soln. (200 .mu.L, contg. human BCDF 2 .mu.g and human serum *albumin* 500 .mu.g) was placed in a vial and freeze-dried. The product was subsequently dissolved in water and used for injection.

L30 ANSWER 6 OF 13 CA COPYRIGHT 1997 ACS

AN 113:103445 CA

TI Stable *interferon* - . *beta* . preparations containing metal salts and albumins

IN Yamazaki, Shojiro; Taniguchi, Makoto; Hara, Michio
PA Toray Industries, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF
PI JP 02124832 A2 900514 Heisei
AI JP 89-174811 890705

PRAI JP 88-171491 880708
DT Patent

LA Japanese

AB *Interferon* - . *beta* . preps., useful for intranasal, intrarectal, and intrapulmonary administration, contain alk. earth metal salts or lanthanide salts and albumins. A Tris buffer soln. contg. 2 .times. 104 IU/mL *interferon* - . *beta* ., 33 .mu.g/mL human serum *albumin* , and 0.5 mM YbCl₃ was stored at 37.degree. for 24 h to show 80% residual potency, vs. 25% of the control prep'd. without *albumin* and YbCl₃.

L30 ANSWER 7 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 1
AN 111:239534 CA

TI *Pharmaceutical* compositions containing recombinant

interferon - . *beta* .

IN Taforo, Terrance; Thomson, Jody; Shaked, Ze'ev; Hershenson, Susan; Thomson, James W.; Stewart, Tracy

PA Cetus Corp., USA

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

PI WO 8902750 A1 890406

DS W: AU, DK, JP, NO

RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

AI WO 88-US3313 880926

PRAI US 87-100679 870929

DT Patent

LA English

AB A stable parenteral compn. in liq. or lyophilized form comprises a recombinant *interferon* - . *beta* . (IFN-.beta.)

protein dissolved in an inert carrier medium contg. nonionic polymeric surfactants as a solubilizer/stabilizer. The surfactants include polyoxyethylene sorbitan fatty acid esters, a mixt. of ethoxylated fatty alc. ethers and lauryl ether, ethoxylated octylphenol, a mixt. of ethoxylated or propoxylated alcs., polyethylene glycol monooleate, ethoxylated phenol, and propylene oxide-ethylene oxide block copolymers. The compn. further comprises addnl. bulking/stabilizing agents, such as dextrose. An IFN-.beta. analog designated as IFN-.beta.ser17 was recovered from Escherichia coli culture media and stabilized by adding 0.15% Trycol LAL-12 and pH was adjusted to 7.0 with NaOH. A bulking/stabilizing agent, i.e., 5% dextrose, was then added and the soln. was sterile-filtered, aseptically filled into vials, and lyophilized. The IFN-.beta. formulations of this invention contain very low levels of aggregates and other potentially immunogenic characterisits and minimal or no strong solubilizing agents, such as SDS, and they are nontoxic and have good shelf life.

L30 ANSWER 8 OF 13 CA COPYRIGHT 1997 ACS

AN 113:65247 CA

TI Stabilization of *interferon* - . *beta* . in *pharmaceuticals*

IN Hara, Michio; Taniguchi, Makoto

PA Toray Industries, Inc., Japan

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

PI WO 8910756 A1 891116

DS W: JP

RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

AI WO 89-JP466 890502

PRAI JP 88-110921 880506

DT Patent

LA Japanese

AB *Interferon* - . *beta* . as a virucide in *pharmaceutical* formulation is stabilized by the presence of 65-90% by wt. polyols and p-hydroxybenzoates. Thus, *interferon* - . *beta* . (1 .times. 105 IU/g) in a *pharmaceutical* contg. glycerin 70.0, Et 4-hydroxybenzoate 0.01, Pr 4-hydroxybenzoate 0.01, CM cellulose 2.50, human serum *albumin* 0.60, 0.1 M citrate buffer (pH 5) 26.88% by wt. was stabilized for at least 52 h.

L30 ANSWER 9 OF 13 CA COPYRIGHT 1997 ACS

AN 110:237165 CA

TI Antitumor *pharmaceuticals* containing *interferons* and dipyridamole

IN Suzuki, Nobuo; Takakubo, Yoshiaki

PA Boehringer Ingelheim International G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

PI EP 295317 A1 881221

DS R: GB

AI EP 87-108708 870616

DT Patent

LA English

AB Dipyridamole (I) or its salt is used in the manuf. of a *pharmaceutical* capable of enhancing the antitumor effect of an *interferon* when administered to a patient who is being treated with the *interferon*. A lyophilizate contained recombinant human *interferon* - .gamma. (2 .times. 106 IU) 2,

human serum *albumin* 10.000, NaCl 1.750, *mannitol* 40.000, polyoxyethylene sorbitan monooleate 0.300, succinic acid 2.36, IN NaOH 36.26 mg, and H₂O to 1.00 mL; this compn. was lyophilized and stoppered. An ampule contained 1 10, tartaric acid 4, polyethylene glycol 100 mg, IN HCl to pH 2.7, H₂O to 2 mL. The lyophilizate above was reconstituted with the contents of the 1-contg. ampule; compns. contg. *interferon* - .alpha.2 and *interferon* - .beta* were stable at room temp. for 6 h, compns. contg. *interferon* - .gamma. should be used immediately after reconstitution. DNA synthesis activity in RSA cells was depressed by 61% with a combination of 1 unit/mL human *interferon* - .gamma. and 0.1 .mu.M I, by 84% with a combination of 1 unit/mL human *interferon* - .gamma. and 0.1 .mu.M mepidamole, and by 91% with 1 unit/mL human *interferon* - .gamma. alone.

L30 ANSWER 10 OF 13 CA COPYRIGHT 1997 ACS

AN 110:179532 CA

TI *Pharmaceutical* injections containing recombinant beta-*interferons* and nonionic surfactants and sugars as stabilizers

IN Shaked, Zeev; Stewart, Tracy; Thomson, Jody; Thomson, James William; Taforo, Terrance; Hershenson, Susan

PA Cetus Corp., USA

SO Eur. Pat. Appl., 83 pp.

CODEN: EPXXDW

PI EP 270799 A1 880615

DS R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

AI EP 87-115693 871026

PRAI US 86-923423 861027

DT Patent

LA English

AB A stable *pharmaceutical* compn. for parenteral administration comprises a recombinant *interferon* - .beta* . (IFN-.beta.) protein dissolved in an inert carrier medium contg. gtoeq.1 biocompatible nonionic polymeric detergent(s) as a solubilizer or stabilizer. The strain of IFN-.beta.ser17-producing E. coli carrying plasmid pSY2501 was cultured. The refractile bodies contg. IFN-.beta.ser17 protein were harvested, concd., and disrupted; EDTA was added to kill residual bacterial and sucrose was added to create a concn. gradient of 1.1-1.25 g/mL and the soln. was centrifuged. The pellet was solubilized in phosphate-buffered saline with 2% Na dodecyl sulfate and dithiothreitol and extd. with 2-butanol. The ext. was again mixed with 0.1% Na dodecyl sulfate in phosphate-buffered saline and dithiothreitol; the mixt. was centrifuged and the pellet contained 81% IFN-.beta.. The pellet was then processed by Sephadryl S200 pre-column chromatog., oxidized by o-iodobenzoic acid, concd., and purified by Sephadex G-75 column. The desalting step was performed at pH 9.2 with Sephadex G-25 column equilibrated with 0.1% Na laurate and the pH of the eluate was lowered to pH 3.0 to ppt. the Na laurate. The mixt. was centrifuged and the supernatant was stabilized by adding 0.15% Trycol LAL-12; the pH was raised to apprx. 7.0 with NaOH and 5g dextrose was then added; finally the soln. was sterile-filtered and the dosage amts. of IFN-.beta.ser17 (0.25 mg) were filled into vials and frozen to between -35 and -45.degree.. A preferred lyophilized normal dose formulation comprises recombinant IFN-.beta. 0.25 mg/mL, polyoxyethylene lauryl ether 0.15% by vol., Na phosphate buffer 20 mM, dextrose 0.2%, and *mannitol* 2%. These IFN-.beta. formulations are at least as stable as human serum *albumin* -contg. formulations and they do not require strong solubilizing agents such as SDS.

L30 ANSWER 11 OF 13 CA COPYRIGHT 1997 ACS

AN 109:216010 CA

TI Controlled-release of macromolecular polypeptides

IN Eppstein, Deborah Ann; Schryver, Brian Bloor

PA Syntex (U.S.A.), Inc., USA

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

PI EP 251476 A1 880107

DS R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

AI EP 87-304570 870522

PRAI US 86-866625 860523

DT Patent

LA English

737633.TRN

AB An active agent delivery system for the controlled administration of a macromol. polypeptide, comprises a polymeric matrix comprising .ltoreq.30% by wt. of particles of polypeptide and other optional water-sol. components dispersed in a polypeptide.

dl-Poly(lactide-glycolide) in acetone and human .beta.-

interferon in a buffer (contg. human serum *albumin* and dextrose) were vortexed and centrifuged to obtain a pellet, which was dissolved in acetone to leave a microsuspension; the assay for *interferon* in the system showed essentially no loss of biol. activity of the incorporated *interferon*. The above microsuspension was then atomized with a spray device and the resulting particles dried and sorted under vacuum for 3 days; the particles 330 mg were suspended in 5.5 mL of the soln. contg. Na CMC 0.5, NaCl 0.6, PhCH₂OH 0.9, Tween 80 0.1, and water to 100%, to provide an injectable dose of 9 .mu.g of *interferon* per 0.5 mL of injectable suspension.

L30 ANSWER 12 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 2
AN 109:215865 CA

TI Enzyme immunoassay of human fibroblast *interferon* after intranasal administration with several excipients in rabbits

AU Igawa, Takeshi; Maitani, Yoshie; Machida, Yoshiharu; Nagai, Tsuneji
CS Fac. Pharm. Sci., Hoshi Univ., Tokyo, 142, Japan

SO Chem. Pharm. Bull. (1988), 36(8), 3055-9

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

AB Human *interferon* - .beta* . (HuIFN-.beta.) titer after intranasal administration was detd. by enzyme immunoassay (EIA), substituting for bioassay. The intranasal absorption was linearly related to HuIFN-.beta. dose. Compared with i.v. administration, the mean bioavailability of intranasal HuIFN-.beta. was 3%. The effects of several excipients, human serum *albumin* (HSA), polyethylene glycol, diethylaminoethyl dextran, carboxypolymethylene, .alpha.-cyclodextrin, and cholesteryl stearate, on the absorption of HuIFN-.beta. were examd. with the powder dosage form. Among these excipients, HSA and .alpha.-cyclodextrin gave the highest HuIFN-.beta. concns. in plasma. The area under the plasma concn.-time curve (AUC) decreased as the mol. wt. of excipients was increased.

L30 ANSWER 13 OF 13 CA COPYRIGHT 1997 ACS DUPLICATE 3
AN 107:183557 CA

TI Improved formulation for recombinant .beta.- *interferon* with protein or sugar stabilizer

IN Hanisch, Wolfgang Helmut; Taforo, Terrance; Fernandes, Peter Michael
PA Cetus Corp., USA

SO Eur. Pat. Appl., 34 pp.

CODEN: EPXXDW

PI EP 215658 A2 870325

DS R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE

AI EP 86-307070 860912

PRAI US 85-775751 850913

DT Patent

LA English

AB Recombinant .beta.-human *interferon* (. *beta* .-HIFN) is dissolved in a non-toxic, inert, therapeutically compatible aq. carrier, at a pH of 2-4. The soln. contains a stabilizer for the .beta.-HIFN, particularly human plasma protein fraction, human serum *albumin*, or *mannitol* .

This formulation results in very low sodium dodecyl sulfate levels.

.beta.- *Interferon* 0.25 mg/mL was formulated using 2.5% plasma protein fraction at pH 3-4, incubated 15-45 min.; the pH was adjusted to 7.3-7.5. At this pH, the solns. were very clear. The use of 5.0% human serum *albumin* also gave clear solns., whereas 2.5% HSA resulted in slightly hazy solns.

=> d his (FILE 'HOME' ENTERED AT 12:40:25 ON 14 APR 1997)

FILE 'MEDLINE' ENTERED AT 12:40:35 ON 14 APR 1997

L1 0 S INTERFERON? AND (COMPOSITION AND (MANNITOL AND ALBUMIN FILE 'MEDLINE, BIOSIS, CA, INPADOC, WPIDS, JICST-EPLUS' ENTERED AT

12:41:34 ON 14 APR 1997 FILE 'MEDLINE, BIOSIS, CA, INPADOC, WPIDS, JICST-EPLUS' ENTERED AT

12:41:37 ON 14 APR 1997

L2 0 FILE MEDLINE

L3 0 FILE BIOSIS

L4 0 FILE CA
 L5 0 FILE INPADOC
 L6 2 FILE WPIDS
 L7 0 FILE JICST-EPLUS
 TOTAL FOR ALL FILES
 L8 2 S INTERFERON? AND (COMPOSITION AND (MANNITOL AND ALBUMIN
 L9 1493 FILE MEDLINE
 L10 1299 FILE BIOSIS
 L11 1408 FILE CA
 L12 4 FILE INPADOC
 L13 210 FILE WPIDS
 L14 388 FILE JICST-EPLUS
 TOTAL FOR ALL FILES
 L15 4802 S INTERFERON? AND ((MANNITOL OR ALBUMIN OR ACETATE))
 L16 48 FILE MEDLINE
 L17 45 FILE BIOSIS
 L18 71 FILE CA
 L19 0 FILE INPADOC
 L20 12 FILE WPIDS
 L21 15 FILE JICST-EPLUS
 TOTAL FOR ALL FILES
 L22 191 S L15 AND INTERFERON BETA
 L23 0 FILE MEDLINE
 L24 0 FILE BIOSIS
 L25 12 FILE CA
 L26 0 FILE INPADOC
 L27 2 FILE WPIDS
 L28 2 FILE JICST-EPLUS
 TOTAL FOR ALL FILES
 L29 16 S L22 AND PHARMACEUT?
 L30 13 DUP REM L29 (3 DUPLICATES REMOVED)
 => s l22 not l29
 L31 48 FILE MEDLINE
 L32 45 FILE BIOSIS
 L33 59 FILE CA
 L34 0 FILE INPADOC
 L35 10 FILE WPIDS
 L36 13 FILE JICST-EPLUS TOTAL FOR ALL FILES
 L37 175 L22 NOT L29
 => dup rem l37
 PROCESSING COMPLETED FOR L37
 L38 121 DUP REM L37 (54 DUPLICATES REMOVED)
 => d 100 ti
 L38 ANSWER 100 OF 121 MEDLINE
 TI Purification of proteins from cell culture supernatants.
 => d 100 so
 L38 ANSWER 100 OF 121 MEDLINE
 SO DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, (1987) 66 391-401.
 Journal code: E7V. ISSN: 0301-5149.
 => d 20 so
 L38 ANSWER 20 OF 121 MEDLINE
 SO CARCINOGENESIS, (1993 Mar) 14 (3) 367-72.
 Journal code: C9T. ISSN: 0143-3334.
 => d 1-50 ti
 L38 ANSWER 1 OF 121 MEDLINE
 TI HMG I(Y) interferes with the DNA binding of NF-AT factors and the induction of the interleukin 4 promoter in T cells.
 L38 ANSWER 2 OF 121 WPIDS COPYRIGHT 1997 DERWENT INFORMATION LTD
 TI Spray dried powder contg. *interferon* for pulmonary delivery - for treating tumours, hepatitis etc. is suitable for long term self admin..
 L38 ANSWER 3 OF 121 MEDLINE
 TI Involvement of the double-stranded-RNA-dependent kinase PKR in *interferon* expression and *interferon* -mediated antiviral activity.
 L38 ANSWER 4 OF 121 MEDLINE
 TI Characteristic biological features of human megakaryoblastic leukaemia cell lines.
 L38 ANSWER 5 OF 121 MEDLINE DUPLICATE 1
 TI Cytokines and growth factors induce HSP27 phosphorylation in human astrocytes.
 L38 ANSWER 6 OF 121 MEDLINE
 TI Tamoxifen, megestrol *acetate*, and beta *interferon* in endometrial cancer.
 L38 ANSWER 7 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI Strategy for the treatment of refractory cancers. II. Chemotherapy for Malignant Melanoma.
 L38 ANSWER 8 OF 121 WPIDS COPYRIGHT 1997 DERWENT INFORMATION LTD
 TI Combinations contg. new antiviral agents and known cpds., e.g. AZT - for treating HIV infection, AIDS and ARC.
 L38 ANSWER 9 OF 121 MEDLINE DUPLICATE 2
 TI *Interferon* - *beta* induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1.
 L38 ANSWER 10 OF 121 MEDLINE
 TI Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation.
 L38 ANSWER 11 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI A case of malignant melanoma successfully treated by DAV chemotherapy and high dose administration of *interferon* - *BETA* ..
 L38 ANSWER 12 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI Neurocutaneous Melanosis. A Case Report.
 L38 ANSWER 13 OF 121 CA COPYRIGHT 1997 ACS
 TI Application of the ATP-cell viability assay for assessment of biologic response modifiers in gynecologic cancer
 L38 ANSWER 14 OF 121 MEDLINE
 TI Involvement of protein kinase C in macrophage activation by poly(I.C).
 L38 ANSWER 15 OF 121 CA COPYRIGHT 1997 ACS
 TI Methods for the treatment of tumors with dipyridamole and *interferons*
 L38 ANSWER 16 OF 121 CA COPYRIGHT 1997 ACS
 TI Chromatographic purification of recombinant human beta *interferon*
 L38 ANSWER 17 OF 121 MEDLINE DUPLICATE 3
 TI Chronic human immunodeficiency virus type 1 infection stimulates distinct NF-kappa B/rel DNA binding activities in myelomonoblastic cells.
 L38 ANSWER 18 OF 121 MEDLINE
 TI Differentiation-dependent activation of *interferon* -stimulated gene factors and transcription factor NF-kappa B in mouse embryonal carcinoma cells.
 L38 ANSWER 19 OF 121 BIOSIS COPYRIGHT 1997 BIOSIS
 TI FLOW CYTOMETRY QUANTIFIES DIFFERENTIAL PHORBOL ESTER AND GLUCOCORTICOID EFFECTS ON CELL SURFACE MOUSE MAMMARY TUMOR VIRUS GP 52 EXPRESSION.
 L38 ANSWER 20 OF 121 MEDLINE
 TI Differential co-promoting activities of alpha, beta and gamma *interferons* in the murine skin two-stage carcinogenesis model.
 L38 ANSWER 21 OF 121 MEDLINE
 TI Inhibition of antigen-induced secretion in the rat jejunum by *interferon* alpha/beta.
 L38 ANSWER 22 OF 121 MEDLINE DUPLICATE 4
 TI Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with *interferon* - *beta* in patients with HB(e)Ag-positive chronic active hepatitis.
 L38 ANSWER 23 OF 121 MEDLINE DUPLICATE 5
 TI Induction of monocytic differentiation and NF-kappa B-like activities by human immunodeficiency virus 1 infection of myelomonoblastic cells.
 L38 ANSWER 24 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI Treatment and Prognosis of Acute Retinal Necrosis.
 L38 ANSWER 25 OF 121 MEDLINE DUPLICATE 6
 TI Human beta- *interferon* incubated with muscle homogenate is protected by *albumin* but not by proteinase inhibitors.
 L38 ANSWER 26 OF 121 MEDLINE DUPLICATE 7
 TI Induction of *interferon* synthesis and cytotoxicity by murine peritoneal macrophages exposed to glycoprotein ligands.
 L38 ANSWER 27 OF 121 MEDLINE

TI Transcriptional activation of human (2'-5')oligoadenylate synthetase gene expression by the phorbol ester 12-O-tetradecanoyl-phorbol 13-acetate* in type-I- *interferon* -treated HL-60 and HeLa cells.
 L38 ANSWER 28 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI Malignant Melanoma Treated with LAK Therapy and *Interferon* - *BETA* ; A Case Report.
 L38 ANSWER 29 OF 121 MEDLINE DUPLICATE 8
 TI The effects of *interferon* - *beta* on phorbol ester or calcium ionophore-induced intercellular adhesion molecule-I expression in epidermal carcinoma cells.
 L38 ANSWER 30 OF 121 MEDLINE
 TI Heterodimerization and transcriptional activation in vitro by NF-kappa B proteins.
 L38 ANSWER 31 OF 121 MEDLINE
 TI Phorbol ester-mediated inhibition of IFN-alpha/beta gene transcription in blood mononuclear leukocytes.
 L38 ANSWER 32 OF 121 CA COPYRIGHT 1997 ACS
 TI Cytokine messenger RNA stability is enhanced in tumor cells
 L38 ANSWER 33 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI Treatment of malignant glioma by in-traarterial infusion of MCNU *interferon* - *BETA* . and *mannitol* .
 L38 ANSWER 34 OF 121 CA COPYRIGHT 1997 ACS
 TI Relationship of acivicin-induced monocytoid differentiation of human myeloid leukemia cells to acivicin-induced modulation of growth factor, cytokine, and protooncogene mRNA expression
 L38 ANSWER 35 OF 121 CA COPYRIGHT 1997 ACS
 TI Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines
 L38 ANSWER 36 OF 121 MEDLINE
 TI *Interferon* type I and II antagonism: a novel regulatory mechanism of indoleamine dioxygenase induction in human peripheral blood monocytes and peritoneal macrophages.
 L38 ANSWER 37 OF 121 BIOSIS COPYRIGHT 1997 BIOSIS
 TI MILK PROTEINS IN THE ETIOLOGY OF INSULIN-DEPENDENT DIABETES MELLITUS
 IDDM.
 L38 ANSWER 38 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI A case of malignant melanoma treated with median plantar flap. An evaluation of the quality of life in a patient with malignant tumor.
 L38 ANSWER 39 OF 121 MEDLINE DUPLICATE 9
 TI Effects of *interferons* on cultured human melanocytes in vitro: *interferon* - *beta* but not-alpha or -gamma inhibit proliferation and all *interferons* significantly modulate the cell phenotype.
 L38 ANSWER 40 OF 121 MEDLINE
 TI Stimulation of *interferon* *beta* gene transcription in vitro by purified NF-kappa B and a novel TH protein.
 L38 ANSWER 41 OF 121 MEDLINE
 TI Priming of human alveolar macrophages and blood monocytes for superoxide anion release by *interferons* and lipopolysaccharide.
 L38 ANSWER 42 OF 121 BIOSIS COPYRIGHT 1997 BIOSIS
 TI CHANGES IN HEPATIC FUNCTION AND ULTRASTRUCTURES OF HEPATOCYTES DURING TREATMENT WITH *INTERFERON* - *BETA* AND A STREPTOCOCCAL PREPARATION OK-432 IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS.
 L38 ANSWER 43 OF 121 CA COPYRIGHT 1997 ACS
 TI Dimethyl sulfoxide inhibits the expression of early growth-response genes and arrests fibroblasts at quiescence
 L38 ANSWER 44 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI In vitro chemosensitivity test with several antitumor agents against eight malignant brain tumor cell-lines.
 L38 ANSWER 45 OF 121 CA COPYRIGHT 1997 ACS
 TI Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure
 L38 ANSWER 46 OF 121 JICST-EPlus COPYRIGHT 1997 JST
 TI A case of malignant melanoma which showed an obvious disappearance tendency of metastatic lesion by DAV+ *interferon* - *BETA* . therapy.
 L38 ANSWER 47 OF 121 JICST-EPlus COPYRIGHT 1997 JST

TI Combined treatment of local injection IFN-.BETA. and intracarotid injection of ACNU to recurrent malignant gliomas.
 L38 ANSWER 48 OF 121 CA COPYRIGHT 1997 ACS
 TI Liver-specific gene expression: A-activator-binding site, a promoter module present in vitellogenin and acute-phase genes
 L38 ANSWER 49 OF 121 CA COPYRIGHT 1997 ACS
 TI Augmentation of haptoglobin production in Hep3B cell line by a nuclear factor NF-IL6
 L38 ANSWER 50 OF 121 CA COPYRIGHT 1997 ACS
 TI Effect of panaxatriol ginsenoside on interleukin-6 mRNA translation => file medline
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 66.14 72.42 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE -5.52 -5.52 FILE 'MEDLINE' ENTERED AT 12:48:43 ON 14 APR 1997 FILE LAST UPDATED: 7 APR 1997 (19970407/UP). FILE COVERS 1966 TO DATE.
 +QLF/CT SHOWS YOU THE ALLOWABLE QUALIFIERS OF A TERM.
 MEDLINE, CANCERLIT AND PDQ ERRONEOUSLY ANNOTATED CERTAIN ARTICLES
 AUTHORED OR CO-AUTHORED BY DR. BERNARD FISHER WITH THE PHRASE
 "SCIENTIFIC MISCONDUCT-DATA TO BE REANALYZED." ALL SUCH ANNOTATIONS
 HAVE BEEN REMOVED OR ARE BEING REMOVED. WE APOLOGIZE FOR ANY PROBLEMS
 OR CONCERNS THIS MAY HAVE CAUSED. USERS SHOULD DISREGARD THOSE PRIOR ANNOTATIONS. MEDLINE ANNUAL RELOAD AVAILABLE ON STN IN RECORD TIME (2/08/97).
 ENTER HELP RLOAD FOR DETAILS. THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.
 => s pharma? and (composition and (mannitol and albumin and acetate))
 1429753 PHARMA?
 85370 COMPOSITION
 9570 MANNITOL
 70099 ALBUMIN
 60488 ACETATE
 L39 0 PHARMA? AND (COMPOSITION AND (MANNITOL AND ALBUMIN AND ACE TATE))
 => s pharma? and ((mannitol and albumin and acetate))
 1429753 PHARMA?
 9570 MANNITOL
 70099 ALBUMIN
 60488 ACETATE
 L40 1 PHARMA? AND ((MANNITOL AND ALBUMIN AND ACETATE))
 => d ti
 L40 ANSWER 1 OF 1 MEDLINE
 TI Studies on the interference of selected substances with two modifications of the Lowry protein determination.
 => s (composition and (mannitol and albumin and acetate))
 85370 COMPOSITION
 9570 MANNITOL
 70099 ALBUMIN
 60488 ACETATE
 L41 0 (COMPOSITION AND (MANNITOL AND ALBUMIN AND ACETATE))
 => s pharmaceutical and ((mannitol and albumin or acetate))
 21018 PHARMACEUTICAL
 9570 MANNITOL
 70099 ALBUMIN
 60488 ACETATE
 L42 218 PHARMACEUTICAL AND ((MANNITOL AND ALBUMIN OR ACETATE))
 => s pharmaceutical and (((mannitol or albumin) and acetate))
 21018 PHARMACEUTICAL
 9570 MANNITOL
 70099 ALBUMIN
 60488 ACETATE

L43 5 PHARMACEUTICAL AND ((MANNITOL OR ALBUMIN) AND ACETATE))
=> d 1-5 ti so au

L43 ANSWER 1 OF 5 MEDLINE
TI Parenteral formulation development of renin inhibitor Abbott-72517.
SO JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, (1994 Mar-Apr) 48 (2) 86-91.
Journal code: B2F. ISSN: 1076-397X.
AU Gupta S L; Patel J P; Jones D L; Partipilo R W

L43 ANSWER 2 OF 5 MEDLINE
TI Freeze-drying and quality evaluation of protein drugs.
SO DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, (1992) 74 307-22.
Journal code: E7V. ISSN: 0301-5149.
AU Inazu K; Shima K

L43 ANSWER 3 OF 5 MEDLINE
TI Combinative improving effect of increased solubility and the use of absorption enhancers on the rectal absorption of uracil in beagle dogs.
SO CHEMICAL AND PHARMACEUTICAL BULLETIN, (1990 Sep) 38 (9) 2547-51.
Journal code: CZP. ISSN: 0009-2363.
AU Takeichi Y; Baba K; Kinouchi Y; Iida Y; Umeno Y; Muranishi S; Nakai Y

L43 ANSWER 4 OF 5 MEDLINE
TI Ethylene-vinyl *acetate* copolymer microspheres for controlled release of macromolecules.
SO JOURNAL OF PHARMACEUTICAL SCIENCES, (1984 Dec) 73 (12) 1859-61.
Journal code: JO7. ISSN: 0022-3549.
AU Sefton M V; Brown L R; Langer R S

L43 ANSWER 5 OF 5 MEDLINE
TI Zero-order controlled-release polymer matrices for micro- and macromolecules.
SO JOURNAL OF PHARMACEUTICAL SCIENCES, (1983 Jan) 72 (1) 17-22.
Journal code: JO7. ISSN: 0022-3549.
AU Hsieh D S; Rhine W D; Langer R
=> d 1-5 ti so au l42

L42 ANSWER 1 OF 218 MEDLINE
TI Controlled-release periodontal chemotherapy: the evolution of antimicrobial delivery systems.
SO PRACTICAL PERIODONTICS AND AESTHETIC DENTISTRY, (1995 Aug) 7 Suppl 1-8.
Journal code: A8A. ISSN: 1042-2722.
AU Rethman J; Rethman M; Suzuki J

L42 ANSWER 2 OF 218 MEDLINE
TI Investigation on the chemical stability of erythromycin in solutions using an optimization system.
SO PHARMACY WORLD AND SCIENCE, (1996 Oct) 18 (5) 182-6.
Journal code: BO7. ISSN: 0928-1231.
AU Brisaert M; Heylen M; Plaizier-Vercammen J

L42 ANSWER 3 OF 218 MEDLINE
TI Time-related induction of DNA repair synthesis in rat hepatocytes following in vivo treatment with cypoterone *acetate*. SO CARCINOGENESIS, (1996 Oct) 17 (10) 2271-4.
Journal code: C9T. ISSN: 0143-3334.
AU Kasper P; Mueller L

L42 ANSWER 4 OF 218 MEDLINE
TI Microencapsulation of an iron chelator for sustained release and crystal habit modification.
SO JOURNAL OF MICROENCAPSULATION, (1996 Sep-Oct) 13 (5) 519-25.
Journal code: JMG. ISSN: 0265-2048.
AU Venkataram S; Khohlokwane M

L42 ANSWER 5 OF 218 MEDLINE
TI Cellulose *acetate* butyrate microparticles for controlled release of carbamazepine.
SO JOURNAL OF MICROENCAPSULATION, (1996 Jul-Aug) 13 (4) 407-17.
Journal code: JMG. ISSN: 0265-2048.
AU Arnaud P; Boue C; Chaumeil J C
=> d l42 2 kwic

L42 ANSWER 2 OF 218 MEDLINE
CT *Antibiotics, Macrolide: CH, chemistry

* Chemistry, Pharmaceutical: MT, methods*
Chemistry, Physical: MT, methods
Drug Stability
*Erythromycin: CH, chemistry
Hydrogen-Ion Concentration
Isosorbide: AA, analogs & derivatives
Isosorbide: CH, chemistry
Kinetics
Solutions
Solvents: CH, chemistry
* Zinc Acetate: CH, chemistry*
RN 114-07-8 (Erythromycin); 5306-85-4 (2,5-dimethylisosorbide); *5970-45-6 (Zinc Acetate)* ; 652-67-5 (Isosorbide)
=> d his (FILE 'HOME' ENTERED AT 12:40:25 ON 14 APR 1997)
FILE 'MEDLINE' ENTERED AT 12:40:35 ON 14 APR 1997
L1 0 S INTERFERON? AND (COMPOSITION AND (MANNITOL AND ALBUMIN FILE 'MEDLINE, BIOSIS, CA, INPADOC, WPIDS, JICST-EPLUS' ENTERED AT 12:41:34 ON 14 APR 1997 FILE 'MEDLINE, BIOSIS, CA, INPADOC, WPIDS, JICST-EPLUS' ENTERED AT 12:41:37 ON 14 APR 1997
L2 0 FILE MEDLINE
L3 0 FILE BIOSIS
L4 0 FILE CA
L5 0 FILE INPADOC
L6 2 FILE WPIDS
L7 0 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L8 2 S INTERFERON? AND (COMPOSITION AND (MANNITOL AND ALBUMIN
L9 1493 FILE MEDLINE
L10 1299 FILE BIOSIS
L11 1408 FILE CA
L12 4 FILE INPADOC
L13 210 FILE WPIDS
L14 388 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L15 4802 S INTERFERON? AND ((MANNITOL OR ALBUMIN OR ACETATE))
L16 48 FILE MEDLINE
L17 45 FILE BIOSIS
L18 71 FILE CA
L19 0 FILE INPADOC
L20 12 FILE WPIDS
L21 15 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L22 191 S L15 AND INTERFERON BETA
L23 0 FILE MEDLINE
L24 0 FILE BIOSIS
L25 12 FILE CA
L26 0 FILE INPADOC
L27 2 FILE WPIDS
L28 2 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L29 16 S L22 AND PHARMACEUT?
L30 13 DUP REM L29 (3 DUPLICATES REMOVED)
L31 48 FILE MEDLINE
L32 45 FILE BIOSIS
L33 59 FILE CA
L34 0 FILE INPADOC
L35 10 FILE WPIDS
L36 13 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L37 175 S L22 NOT L29
L38 121 DUP REM L37 (54 DUPLICATES REMOVED) FILE
'MEDLINE' ENTERED AT 12:48:43 ON 14 APR 1997
L39 0 S PHARMA? AND (COMPOSITION AND (MANNITOL AND ALBUMIN AND
L40 1 S PHARMA? AND ((MANNITOL AND ALBUMIN AND ACETATE))
L41 0 S (COMPOSITION AND (MANNITOL AND ALBUMIN AND ACETATE))
L42 218 S PHARMACEUTICAL AND ((MANNITOL AND ALBUMIN OR ACETATE))

L43 5 S PHARMACEUTICAL AND ((MANNITOL OR ALBUMIN) AND ACETATE)
=> s pharmaceutical and (((mannitol and albumin) or acetate))
21018 PHARMACEUTICAL
9570 MANNITOL
70099 ALBUMIN
60488 ACETATE
L44 218 PHARMACEUTICAL AND ((MANNITOL AND ALBUMIN) OR ACETATE))
=> d 10-30 ti
L44 ANSWER 10 OF 218 MEDLINE
TI Analysis of *pharmaceutical* creams: a useful approach based on solid-phase extraction (SPE) and UV spectrophotometry.
L44 ANSWER 11 OF 218 MEDLINE
TI Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation.
L44 ANSWER 12 OF 218 MEDLINE
TI Simple production of [1-carbon-11] *acetate* .
L44 ANSWER 13 OF 218 MEDLINE
TI The effects of corticosteroids of adenoviral replication.
L44 ANSWER 14 OF 218 MEDLINE
TI Deviation of the ratio of drugs in a two-component mixture encapsulated in cellulose phthalate microspheres.
L44 ANSWER 15 OF 218 MEDLINE
TI Studies on development of *pharmaceutical* preparation with the purpose of improving controlled-release and bioavailability.
L44 ANSWER 16 OF 218 MEDLINE
TI The empty follicle syndrome: a *pharmaceutical* industry syndrome [see comments].
L44 ANSWER 17 OF 218 MEDLINE
TI Liquid chromatography combined with thermospray and continuous-flow fast atom bombardment mass spectrometry of glycosides in crude plant extracts.
L44 ANSWER 18 OF 218 MEDLINE
TI Enthalpy and entropy contributions to the solubility of sulphamethoxypyridazine in solvent mixtures showing two solubility maxima.
L44 ANSWER 19 OF 218 MEDLINE
TI Chemotherapy of uterine endometrial cancer.
L44 ANSWER 20 OF 218 MEDLINE
TI Determination of vitamin A, vitamin E, and their esters in tablet preparations using supercritical fluid extraction and HPLC.
L44 ANSWER 21 OF 218 MEDLINE
TI Crystal structure of 2-debenzoyl, 2-acetoxy paclitaxel (Taxol): conformation of the paclitaxel side-chain.
L44 ANSWER 22 OF 218 MEDLINE
TI Stability of angesin solution.
L44 ANSWER 23 OF 218 MEDLINE
TI Structures of nanoparticles prepared from oil-in-water emulsions.
L44 ANSWER 24 OF 218 MEDLINE
TI Solubilization of nicardipine hydrochloride via complexation and salt formation.
L44 ANSWER 25 OF 218 MEDLINE
TI Chemical reagents as potential impurities of *pharmaceutical* products: investigations on their genotoxic activity.
L44 ANSWER 26 OF 218 MEDLINE
TI Influence of emulsifying agents on the properties of cellulose *acetate* butyrate and ethylcellulose microcapsules.
L44 ANSWER 27 OF 218 MEDLINE
TI Properties of free films prepared from aqueous polymers by a spraying technique.
L44 ANSWER 28 OF 218 MEDLINE
TI Comparison of three formulations of calcium *acetate* tablets to evaluate tolerance and control of hyperphosphatemia in patients with chronic renal failure [letter].
L44 ANSWER 29 OF 218 MEDLINE
TI N-methyl-2-pyrrolidone as a cosolvent: relationship of cosolvent effect with solute polarity and the presence of proton-donating groups on model drug compounds.
L44 ANSWER 30 OF 218 MEDLINE
TI Preservative efficacy in cefuroxime and ceftazidime eye drop formulations.
=> s drug# and ((mannitol and albumin and acetate))

1936424 DRUG#
9570 MANNITOL
70099 ALBUMIN
60488 ACETATE
L45 0 DRUG# AND ((MANNITOL AND ALBUMIN AND ACETATE))
=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 4.40 76.82 DISCOUNT AMOUNTS (FOR
QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -5.52 STN INTERNATIONAL LOGOFF
AT 12:56:42 ON 14 APR 1997